Showing results (11-20 of 32) with videos related to
Sort By:
Pageof 4
Pharmacoeconomics|June 27, 2022
Cost-Effectiveness Analysis of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) for the Primary Staging of Prostate Cancer in AustraliaRachel Song, Varinder Jeet, Rajan Sharma, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 14, 2011
Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -intolerant chronic phase chronic myeloid leukemiaMartin Hoyle, Gabriel Rogers, Tiffany Moxham, et al.Seminars in Nuclear Medicine|April 2, 2023
Histopathologically Validated Diagnostic Accuracy of PSMA-PET/CT in the Primary and Secondary Staging of Prostate Cancer and the Impact of PSMA-PET/CT on Clinical Management: A Systematic Review and Meta-analysisVarinder Jeet, Bonny Parkinson, Rachel Song, et al.Pharmacoeconomics|August 24, 2024
Bring Out Your Dead: A Review of the Cost Minimisation Approach in Health Technology Assessment Submissions to the Australian Pharmaceutical Benefits Advisory CommitteeZachary Tirrell, Alicia Norman, Martin Hoyle, et al.Pharmacoeconomics|November 15, 2024
Unravelling the Association Between Uncertainties in Model-based Economic Analysis and Funding Recommendations of Medicines in AustraliaQunfei Chen, Martin Hoyle, Varinder Jeet, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 7, 2009
Cost-effectiveness of temsirolimus for first line treatment of advanced renal cell carcinomaMartin Hoyle, Colin Green, Jo Thompson-Coon, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 30, 2013
Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancerMartin Hoyle, Jaime Peters, Louise Crathorne, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 7, 2009
Cost-effectiveness of sorafenib for second-line treatment of advanced renal cell carcinomaMartin Hoyle, Colin Green, Jo Thompson-Coon, et al.Pharmacoeconomics|March 3, 2018
Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in EnglandIrina A Tikhonova, Nicola Huxley, Tristan Snowsill, et al.Pharmacoeconomics|September 16, 2017
Olaratumab in Combination with Doxorubicin for the Treatment of Advanced Soft Tissue Sarcoma: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology AppraisalIrina A Tikhonova, Tracey Jones-Hughes, James Dunham, et al.Pageof 4